

STAKEHOLDER BRIEFING

DECEMBER 2022

For distribution to: GM Primary Care Networks

Cholesterol management and secondary prevention of cardiovascular disease – updates for Greater Manchester

Background

Cardiovascular disease (CVD) causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas.

Risk factors that contribute to CVD, such as a high cholesterol, are more prevalent in groups of lower socio-economic status, and there is a clear link between societal inequality and poorer CVD outcomes.^{1 2}

The biggest area where the NHS can save lives over the next 10 years is in reducing the incidence of CVD, through targeted approaches to reduce the widening of health inequalities.

Hypercholesterolaemia (high blood cholesterol) is a significant risk factor for CVD, and evidence suggests that improving the detection of those with hypercholesterolaemia and ensuring they received effective treatment will have significant benefits.

National Lipids Optimisation Programme

The AHSN Network is delivering a 3-year National Lipids Optimisation Programme³, which aims to improve the management of cholesterol, increase the detection of those with Familial Hypercholesterolaemia and optimise the use of all medicines for patients on the cholesterol management pathway.

Working in partnership with the Accelerated Access Collaborative (AAC) Rapid Uptake Products (RUP) lipid management programme, the AHSN Network are working to improve patient access to appropriate medicines on the lipids management pathway using the NICE-recommended clinical pathway, alongside other factors such as lifestyle changes.

How can we reduce the incidence of CVD across Greater Manchester?

Health Innovation Manchester is working on a wide programme of work across Greater Manchester to improve CVD patient care and outcomes.

CVD Prevention Resources

1. GMMMG approved lipid pathway

- Created in collaboration with healthcare professionals across the Greater Manchester system and approved by GMMMG, healthcare professionals can now access the Greater Manchester lipid pathway. This pathway complements the [NHSE/NICE Lipid pathway \(Dec 2022\)](#) which provides national guidance for lipid management for primary and secondary prevention of CVD.
- **Access the Greater Manchester lipid pathway [here](#).**

2. GM CVD prevention lipid management case finding tool

- Searches for the identification of high-risk people requiring lipid optimisation for secondary prevention of CVD have been developed. The searches risk-stratify patients into five cohort groups depending on intervention required and includes eligibility for injectable therapies. This is part of the Greater Manchester Integrated Care Systems CVD prevention initiative.
- The numbers of patients identified will include the initial 'back log', as this is the first case finding tool launched for lipid management for secondary prevention of CVD. Consequently, in the future the patient lists will decrease to more manageable numbers.
- In early 2023 there will be additional support offers available to primary care for working through the initial patient lists
- **Access guidance for case finding using TPP System One [here](#)**
- **Access guidance for case finding using EMIS [here](#)**

3. Inclisiran Prescribing, Ordering and Cost Information

- Approved by NICE and listed as Green by GMMMG, Inclisiran is an injection-based lipid treatment to reduce LDL cholesterol. It has been identified by NHS England and NHS Improvement as a medicine that can help tackle lipid management in a large high-risk patient population.
- Inclisiran addresses a current gap in the range of treatment options available for people with Atherosclerotic cardiovascular disease in who lipid targets cannot be met on maximally tolerated statin treatment or with other lipid-lowering therapies.
- **Access Inclisiran prescribing, ordering and cost information [here](#).**
- **Access the Patient Information Leaflet for Inclisiran and cholesterol [here](#).**

All resources for CVD prevention in Greater Manchester can be accessed on the [Health Innovation Manchester website](#).

Educational Webinars

Educational webinars are now available to learn more about CVD prevention for patients across Greater Manchester. Note: completion of these webinars will count towards CVD portfolio points.

1. Lipid management for secondary prevention of CVD
 - Covers the importance of lowering cholesterol; information on measuring blood lipid profiles; an overview of the lipid management pathway; the role of statins in lipid management; how to optimise lipid treatment of patients with established CVD; guidance for Familial Hypercholesterolaemia and Hypertriglyceridemia; and case findings.
 - **Access the webinar [here](#).**
2. Inclisiran: information, guidance and prescribing
 - Covers inclisiran use, safety, efficacy and side effects, NICE and GMMMG guidelines; information for prescribing, administration, ordering, inclisiran case findings and models of care.
 - **Access the webinar [here](#).**

Save the Date: Managing Cholesterol in Greater Manchester

- We invite health care professionals across Greater Manchester primary care to the launch of a new lipid pathway for secondary prevention of CVD.
 - Wednesday 11 January 2023
 - Time: 17:00-18:30 GMT
 - Where: Virtual (MS Teams)
- We welcome all primary care healthcare professionals working in CVD treatment and management to attend
- **Register here: <https://www.eventbrite.co.uk/e/479883874587>**


As part of the educational programme for healthcare professionals '[Tackling Cholesterol Together](#)', the next webinar 'Novel Injectable Therapies Across the Lipid Management Pathway' is on 14 December 2022 at 06:30 PM. Register [here](#).

Greater Manchester data for cholesterol management for secondary prevention of CVD


See below for numbers of CVD patients in each locality falling into specific cohort groups depending on intervention required.

GMSS CVD prevention: lipid management case finding:

1. COHORT 1: Number of patients by locality who have had a CVD event and are not on a statin:



2. COHORT 4: Number of patients by locality who have had a CVD event, are on optimal statins or intolerance confirmed, and lipid levels are not at target. (Target: LDL-C less than 1.8mmol/L or non-HDL-C less than 2.5mmol/L, see GMMM lipid management pathway)



Contact

Please direct any queries to info@healthinnovationmanchester.com

Further Resources

¹ Heart UK's Closing the Cholesterol gap report: <https://www.heartuk.org.uk/news/latest/post/173-closing-the-cholesterol-gap>

² CVDPREVENT: <https://www.nhsbenchmarking.nhs.uk/cvdpreventlanding>

³ National Lipids Optimisation Programme: <https://www.ahsnetwork.com/about-academic-health-science-networks/national-programmes-priorities/lipid-management-and-fh>